Trial · NCT01214603
Results by group55
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 55
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) | Cohort 1, 40 mg LY2090314: D1, D8, D15 | Study Drug-Related AE(s) | 6 | Participants | |
| Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) | Cohort 2, 40 mg LY2090314: D1, D5, D9 | Study Drug-Related AE(s) | 5 | Participants | |
| Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) | Cohort 3, 40 mg LY2090314: D1, D5, D9, D12 | Study Drug-Related AE(s) | 6 | Participants | |
| Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) | Cohort 1, 40 mg LY2090314: D1, D8, D15 | Study Drug-Related SAE(s) | 0 | Participants | |
| Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) | Cohort 2, 40 mg LY2090314: D1, D5, D9 | Study Drug-Related SAE(s) | 2 | Participants | |
| Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs) | Cohort 3, 40 mg LY2090314: D1, D5, D9, D12 | Study Drug-Related SAE(s) | 1 | Participants | |
| Number of Participants With Best Response of Complete Response or Partial Response | Cohort 1, 40 mg LY2090314: D1, D8, D15 | CR | 0 | Participants | |
| Number of Participants With Best Response of Complete Response or Partial Response | Cohort 2, 40 mg LY2090314: D1, D5, D9 | CR | 0 | Participants | |
| Number of Participants With Best Response of Complete Response or Partial Response | Cohort 3, 40 mg LY2090314: D1, D5, D9, D12 | CR | 0 | Participants | |
| Number of Participants With Best Response of Complete Response or Partial Response | Cohort 1, 40 mg LY2090314: D1, D8, D15 | PR | 0 | Participants | |
| Number of Participants With Best Response of Complete Response or Partial Response | Cohort 2, 40 mg LY2090314: D1, D5, D9 | PR | 0 | Participants | |
| Number of Participants With Best Response of Complete Response or Partial Response | Cohort 3, 40 mg LY2090314: D1, D5, D9, D12 | PR | 0 | Participants | |
| Percentage of Participants With Best Response of Complete Response or Partial Response | Cohort 1, 40 mg LY2090314: D1, D8, D15 | CR | 0.0 | percentage of participants | |
| Percentage of Participants With Best Response of Complete Response or Partial Response | Cohort 2, 40 mg LY2090314: D1, D5, D9 | CR | 0.0 | percentage of participants | |
| Percentage of Participants With Best Response of Complete Response or Partial Response | Cohort 3, 40 mg LY2090314: D1, D5, D9, D12 | CR | 0.0 | percentage of participants | |
| Percentage of Participants With Best Response of Complete Response or Partial Response | Cohort 1, 40 mg LY2090314: D1, D8, D15 | PR | 0.0 | percentage of participants | |
| Percentage of Participants With Best Response of Complete Response or Partial Response | Cohort 2, 40 mg LY2090314: D1, D5, D9 | PR | 0.0 | percentage of participants | |
| Percentage of Participants With Best Response of Complete Response or Partial Response | Cohort 3, 40 mg LY2090314: D1, D5, D9, D12 | PR | 0.0 | percentage of participants | |
| Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time 0 to 8 Hours (h) Postdose [AUC(0-8)] | Entire Study Population | 898 | Geometric Coefficient of Variation 47 | nanograms*hours per milliliter (ng*h/mL) | |
| PK: AUC From Time 0 to Infinity [AUC(0-inf)] | Entire Study Population | 963 | Geometric Coefficient of Variation 46.4 | ng*h/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01214603/results